Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer

Purpose: Survivin (BIRC5) is a promising tumor biomarker. Conflicting data exist on its prognostic effect in breast cancer. These data may at least be partly due to the manual interpretation of immunohistochemical staining, especially as survivin can be located in both the nucleus and cytoplasm. Quantitative determination of survivin expression using image analysis offers the opportunity to develop alternative scoring models for survivin immunohistochemistry. Here, we present such a model. Experimental Design: A breast cancer tissue microarray containing 102 tumors was stained with an anti-survivin antibody. Whole-slide scanning was used to capture high-resolution images. These images were analyzed using automated algorithms to quantify the staining. Results: Increased nuclear, but not cytoplasmic, survivin was associated with a reduced overall survival (OS; P = 0.038) and disease-specific survival (P = 0.0015). A high cytoplasmic-to-nuclear ratio (CNR) of survivin was associated with improved OS (P = 0.005) and disease-specific survival (P = 0.05). Multivariate analysis revealed that the survivin CNR was an independent predictor of OS (hazard ratio, 0.09; 95% confidence interval, 0.01-0.76; P = 0.027). A survivin CNR of >5 correlated positively with estrogen receptor (P = 0.019) and progesterone receptor (P = 0.033) levels, whereas it was negatively associated with Ki-67 expression (P = 0.04), p53 status (P = 0.005), and c-myc amplification (P = 0.016). Conclusion: Different prognostic information is supplied by nuclear and cytoplasmic survivin in breast cancer. Nuclear survivin is a poor prognostic marker in breast cancer. Moreover, CNR of survivin, as determined by image analysis, is an independent prognostic factor.

[1]  G. Serio,et al.  p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. , 1992, American journal of clinical pathology.

[2]  T. Visakorpi,et al.  Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. , 1992, Journal of the National Cancer Institute.

[3]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[4]  Fengzhi Li,et al.  Control of apoptosis and mitotic spindle checkpoint by survivin , 1998, Nature.

[5]  G. Landberg,et al.  Telomerase activity in relation to p53 status and clinico‐pathological parameters in breast cancer , 1998, International journal of cancer.

[6]  G. Landes,et al.  Analysis of human transcriptomes , 1999, Nature Genetics.

[7]  K. Tanaka,et al.  Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  D. Altieri,et al.  Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. , 2002, Journal of cell science.

[9]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[10]  Jian Kuang,et al.  Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. , 2002, Molecular biology of the cell.

[11]  G. Landberg,et al.  The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node , 2002, Oncogene.

[12]  L. O’Driscoll,et al.  Lack of prognostic significance of survivin, survivin-ΔEx3, survivin-2B, galectin-3, bag-1, bax-α and MRP-1 mRNAs in breast cancer , 2003 .

[13]  L. O’Driscoll,et al.  Prognostic importance of survivin in breast cancer , 2003, British Journal of Cancer.

[14]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[15]  Chiun-Sheng Huang,et al.  Immunohistochemical analysis of survivin expression in primary breast cancers. , 2004, Journal of the Formosan Medical Association = Taiwan yi zhi.

[16]  William C Earnshaw,et al.  Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. , 2004, The Journal of cell biology.

[17]  L. Rydén,et al.  Tumor Specific VEGF-A and VEGFR2/KDR Protein are Co-expressed in Breast Cancer , 2003, Breast Cancer Research and Treatment.

[18]  Ryoma Ohi,et al.  The Chromosomal Passenger Complex Is Required for Chromatin-Induced Microtubule Stabilization and Spindle Assembly , 2004, Cell.

[19]  P. Span,et al.  Survivin is an independent prognostic marker for risk stratification of breast cancer patients. , 2004, Clinical chemistry.

[20]  S. Horvath,et al.  Global histone modification patterns predict risk of prostate cancer recurrence , 2005, Nature.

[21]  Michael C. Ostrowski,et al.  ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis , 2005, Oncogene.

[22]  D. Tan,et al.  Nuclear or cytoplasmic expression of survivin: What is the significance? , 2005, International journal of cancer.

[23]  Steve Horvath,et al.  Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma , 2005, Modern Pathology.

[24]  P. Span,et al.  High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer , 2006, Breast Cancer Research and Treatment.

[25]  D. Higgins,et al.  Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response , 2005, Expert opinion on biological therapy.

[26]  S. Hewitt,et al.  Infrared spectroscopic imaging for histopathologic recognition , 2005, Nature Biotechnology.

[27]  R. Millikan,et al.  CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance , 2006, Clinical Cancer Research.

[28]  S. Kahlert,et al.  Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  S. Wheatley,et al.  Separating the Anti-apoptotic and Mitotic Roles of Survivin* , 2006, Journal of Biological Chemistry.

[30]  R. Stauber,et al.  The Survivin–Crm1 interaction is essential for chromosomal passenger complex localization and function , 2006, EMBO reports.

[31]  T. Eberlein.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .

[32]  M. Duffy,et al.  Survivin: a promising tumor biomarker. , 2007, Cancer letters.

[33]  I. Petersen,et al.  Nuclear export is essential for the tumor‐promoting activity of survivin , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  Peter A Dervan,et al.  Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. , 2007, Cancer genomics & proteomics.

[35]  R. Walker,et al.  Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients , 2007, British Journal of Cancer.

[36]  Aedín C Culhane,et al.  CENP‐F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer , 2007, International journal of cancer.

[37]  W. Mann,et al.  Survivin’s Dual Role: An Export’s View , 2007, Cell cycle.

[38]  T. Schlange,et al.  Novel c‐MYC target genes mediate differential effects on cell proliferation and migration , 2007, EMBO reports.